Skip to content

Axsome Therapeutics AXSM Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$64.54M-126%-$28.56M+39.5%-$47.23M+1.6%-$47.97M+19.3%-$59.41M+20.7%
$116K+1.8%$114K-5.0%$120K0.0%$120K-19.5%$149K+15.5%
$23.44M+3.1%$22.73M-1.6%$23.1M-6.1%$24.61M+5.6%$23.31M+6.0%
-$20.7M-11.0%-$18.65M$0+100%-$32.42M+25.2%-$43.38M-65.5%
$121K+70.4%$71K+22.4%$58K+346%$13K-96.2%$338K+1,027%
-$121K-70.4%-$71K-22.4%-$58K-346%-$13K+96.2%-$338K-1,027%
$70M0.0%$70M0.0%$70M
$2.99M-81.7%$16.39M-23.0%$21.27M-38.4%$34.54M+18.0%$29.27M+105%
-$17.83M$22.26M-$14.44M-20.5%
-$20.82M-11.2%-$18.72M$0+100%-$32.44M+25.8%-$43.71M-66.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Axsome Therapeutics generate?
Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
What is Axsome Therapeutics's free cash flow?
After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
Where does Axsome Therapeutics's cash flow data come from?
Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.